Literature DB >> 1400886

Histomorphological and immunohistochemical evidence that human nodular goiters grow by episodic replication of multiple clusters of thyroid follicular cells.

H Studer1, H Gerber, J Zbaeren, H J Peter.   

Abstract

This study was aimed at dissecting the cellular mechanisms that underly the growth of actively expanding human goiter nodules. Thirty-two nodules from different patients, all removed because of steady recent growth, were serially sectioned and screened for 1) histomorphological signs of cell proliferation and 2) in situ expression of the immunohistochemically stained p21ras protooncogene product. Bovine, porcine, and rat thyroid glands (the latter from both T4- and perchlorate-treated animals) were used as controls. In normal glands, only a few follicular cells contain substantial amounts of stainable p21ras. Some of these cells are unusually large, but do not proliferate. In contrast, all goiter nodules contain areas where the epithelial cells are morphologically grossly altered and heavily loaded with p21ras. Cells of this type are mostly clustered in large cohorts coating whole follicles or entire groups of follicles. Only a small fraction of these activated cells actually proliferates at any one point in time. Actively replicating cells are scattered in tiny foci all over the nodules. The earliest proliferating buds are solid, but soon begin to generate microfollicles that enlarge by adding new cells to the follicular epithelium. Regionally heterogeneous p21ras content in morphologically identical cells suggests that growth occurs in bursts and waves. We conclude that goiter nodules grow by episodic proliferation of heterogeneous cohorts of epithelial cells from which new follicles are generated. Only a tiny fraction of all goiter cells proliferate at any one point in time. The molecular mechanisms governing these growth processes are unknown.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1400886     DOI: 10.1210/jcem.75.4.1400886

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  Clonality in Thyroid Nodules: The Hyperplasia-Neoplasia Sequence.

Authors:  Zubair W. Baloch; Virginia A. LiVolsi
Journal:  Endocr Pathol       Date:  1998       Impact factor: 3.943

2.  HMG-CoA reductase inhibitors inhibit rat propylthiouracil-induced goiter by modulating the ras-MAPK pathway.

Authors:  Chiara Laezza; Gherardo Mazziotti; Laura Fiorentino; Patrizia Gazzerro; Giuseppe Portella; Diego Gerbasio; Carlo Carella; Giuseppe Matarese; Maurizio Bifulco
Journal:  J Mol Med (Berl)       Date:  2006-09-01       Impact factor: 4.599

3.  Impact of surgical technique on operative morbidity and its socioeconomic benefit in thyroid surgery.

Authors:  Anita Kurmann; Forian Martens; Roman Inglin; Stefan W Schmid; Daniel Candinas; Christian A Seiler
Journal:  Langenbecks Arch Surg       Date:  2012-07-18       Impact factor: 3.445

4.  Overexpression of stimulatory G protein alpha-subunit is a hallmark of most human somatotrophic pituitary tumours and is associated with resistance to GH-releasing hormone.

Authors:  C Hamacher; M Bröcker; E F Adams; T Lei; R Fahlbusch; M Buchfelder; M Derwahl
Journal:  Pituitary       Date:  1998-04       Impact factor: 4.107

5.  Thyroid gland surgery in an endemic region.

Authors:  C A Seiler; C Glaser; H E Wagner
Journal:  World J Surg       Date:  1996-06       Impact factor: 3.352

6.  Extended resection for thyroid disease has less operative morbidity than limited resection.

Authors:  Christian A Seiler; Stephan A Vorburger; Ulrich Bürgi; Daniel Candinas; Stefan W Schmid
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

7.  Serum hepatocyte growth factor is increased in Hashimoto's thyroiditis whether or not it is associated with nodular goiter as compared with healthy non-goitrous individuals.

Authors:  R M Ruggeri; S Sciacchitano; A Vitale; P Cardelli; M Galletti; E Vitarelli; G Barresi; S Benvenga; F Trimarchi; M Trovato
Journal:  J Endocrinol Invest       Date:  2009-03-25       Impact factor: 4.256

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.